IIPLA News
Wednesday, March 4, 2026
PatentsUSA

Moderna Reaches Landmark $2.25 Billion Settlement with Genevant and Arbutus Over LNP Patent Dispute

Global agreement resolves U.S. and international litigation on lipid nanoparticle technology used in COVID-19 vaccines, averting imminent Delaware jury trial

IIPLA News Desk•anonymous access•0 articles left this week
Moderna Reaches Landmark $2.25 Billion Settlement with Genevant and Arbutus Over LNP Patent Dispute
Sign In To Continue

You have reached the guest article limit.

Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.

Sign in with SSOBecome a paid member
Moderna, Genevant Sciences, and Arbutus Biopharma have finalized a global settlement addressing patent infringement claims related to lipid nanoparticle (LNP) delivery technology integral to Moderna’s COVID-19 vaccines. The deal includes an upfront payment of $950 million and potential additional payments up to $1.3 b…
Share This Article
Ready-to-post copy includes the article link.

Moderna Reaches Landmark $2.25 Billion Settlement with Genevant and Arbutus Over LNP Patent Dispute Moderna, Genevant Sciences, and Arbutus Biopharma have finalized a global settlement addressing patent infringement claims related to lipid nanoparticle (LNP) delivery technology integral to Moderna’s COVID-19 vaccines.... Read the full IIPLA article: https://iipla.org/news/moderna-reaches-landmark-2-25-billion-settlement-with-genevant-and-arbutus-over-lnp-patent-dispute

LinkedInXFacebookWhatsAppTelegramEmail
Related Coverage

Continue in the newsroom

Back to newsroom
PatentsUK

UK Intellectual Property Office Issues Patent Journal Special Notices 7152

The UK Intellectual Property Office has published Patent Journal special notices number 7152, featuring key announcements related to Intellectual Property policy and recent additions to the British Library. These notices aim to inform stakeholders about ongoing developments and resources in the IP sector.

Wednesday, June 17, 2026